(PTGX) Protagonist Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PTGX) Protagonist Therapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Protagonist Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Rusfertide (PTG-300) Phase 3 VERIFY
Rusfertide (PTG-300) is Protagonist Therapeutics' lead late-stage asset and a first-in-class hepcidin mimetic. It was in Phase 3 VERIFY for polycythemia vera at the end of 2025, a disease that affects about 100,000 people in the U.S. If approved, it could become Protagonist's first commercial product and the main growth driver.
Icotrokinra (PN-235/JNJ-2113) Phase 3 Psoriasis
Icotrokinra (PN-235/JNJ-2113) is Protagonist Therapeutics, Inc.’s partnered oral IL-23 receptor antagonist licensed to Janssen, and it advanced into Phase 3 in plaque psoriasis in 2025. Plaque psoriasis affects about 125 million people worldwide, so the addressable immune-dermatology market is large and still growing. That mix of late-stage development and big market demand fits a Star in the BCG Matrix.
Icotrokinra Psoriatic Arthritis Expansion
Psoriatic arthritis is a natural next step for icotrokinra because about 30% of people with psoriasis can develop it, widening the same oral IL-23 path beyond skin disease. For Protagonist Therapeutics, Inc., that kind of label expansion can lift peak-sales potential and extend royalty value from one asset. More approved uses also make the program less dependent on a single market.
Icotrokinra Ulcerative Colitis Program
Icotrokinra could be a "Star" if Protagonist Therapeutics proves oral efficacy in ulcerative colitis, a biologics-led market that still grew in 2025. UC affects about 1 in 250 people in Western markets, and oral dosing could win share if it matches injectable remission rates and safety. That would give Protagonist Therapeutics a second growth engine beyond its other pipeline assets.
- High-value, growing UC market
- Oral dosing may improve uptake
- Efficacy is the key swing factor
- Success could add major growth
Janssen Collaboration on IL-23R
Janssen's IL-23R deal validates Protagonist Therapeutics, Inc.'s peptide platform at Johnson & Johnson scale. The pact brought $50 million upfront and up to $755 million in milestones plus royalties, so Protagonist can grow without building a full sales team.
That mix of third-party validation and high-margin economics makes the collaboration one of Protagonist Therapeutics, Inc.'s strongest Stars. It also turns clinical success into durable cash flow if icotrokinra keeps advancing.
- Large-pharma validation
- Upfront cash plus milestones
- Royalty upside, no sales buildout
Icotrokinra: Protagonist's Star Asset Hits Phase 3
Icotrokinra is Protagonist Therapeutics, Inc.'s clearest Star: Janssen moved it into Phase 3 in 2025, with $50 million upfront and up to $755 million in milestones plus royalties. Plaque psoriasis affects about 125 million people worldwide, so the oral IL-23 market is large. Psoriatic arthritis and ulcerative colitis could extend the same asset into more high-value uses.
| Star asset | Key data |
|---|---|
| Icotrokinra | Phase 3, $50M upfront, $755M milestones, royalties |
What is included in the product
Detailed Word Document
Protagonist Therapeutics’ BCG Matrix maps its pipeline for stars, cash cows, question marks, and dogs to guide invest-or-prune decisions.
Editable Excel File
BCG Matrix snapshot of Protagonist Therapeutics, Inc., easing portfolio review and strategic prioritization.
Reference Sources
Provides a traceable source trail for Protagonist Therapeutics, Inc. that strengthens credibility and speeds smarter investment decisions.
Cash Cows
Janssen Collaboration Revenue
Janssen collaboration revenue is Protagonist Therapeutics, Inc.’s closest thing to cash flow, since it is recurring, non-dilutive, and tied to the partnered icotrokinra program. In 2024, Protagonist reported $87.4 million in collaboration revenue, helping fund R&D while it had no marketed product.
This cash cow supports operations and reduces dilution risk, which matters for a pipeline-stage Company. As long as Janssen keeps advancing the program, this revenue stream should remain a key funding base while Protagonist waits for product sales.
Upfront License Economics
Protagonist Therapeutics, Inc. turned PN-235 into upfront cash through its Janssen deal, which reportedly included about $125 million upfront and up to $1.2 billion in milestones and royalties. That monetizes the platform before launch, so the company can capture value without funding a full sales buildout. It is a mature, low-capex cash flow model, not a heavy standalone commercial push.
Milestone Receipts
Milestone receipts are a cash cow for Protagonist Therapeutics, Inc. because partnered programs can trigger non-dilutive payments when they hit clinical and regulatory gates.
The Janssen-linked deal is the key driver: it gives Protagonist Therapeutics, Inc. cash without issuing new shares, helping protect dilution and support a pipeline that still needs heavy R&D spend.
That matters because Protagonist Therapeutics, Inc. has relied on partner funding to back programs like rusfertide and icotrokinra, so each milestone payment can extend runway and fund the next trial step.
Cost Reimbursement Under Partnership
Protagonist Therapeutics, Inc. treats cost reimbursement under partnership as a cash-cow-like stream: shared development can offset about 50% of joint R&D spend, cutting net burn and stretching runway. That matters in 2025, when the Company still carried a large research load before product sales.
- Lower net R&D outlay
- Preserves cash runway
- Supports development without sales
Cash and Marketable Securities
At end-2025, Protagonist Therapeutics’ cash and marketable securities were a key support asset, giving the company room to fund R&D while it waited for product revenue to scale. Interest income on that treasury helped offset operating losses, so the cash pile acted like a buffer, not a business model.
- Treasury cushioned 2025 losses.
- Interest income reduced cash burn.
- Stability, not revenue replacement.
Protagonist’s Cash Cow Is Partner Cash, Not Product Sales
Protagonist Therapeutics, Inc.’s cash cows are partner-driven, not product sales. Janssen collaboration revenue was $87.4 million in 2024, and the deal carried about $125 million upfront plus up to $1.2 billion in milestones and royalties.
That non-dilutive cash helps fund R&D and cut burn while the Company waits for launches. It is steady support, but it is still tied to partner progress, not a mature in-house sales engine.
| Cash Cow Driver | Latest Data | Why It Matters |
|---|---|---|
| Janssen collaboration revenue | $87.4M in 2024 | Recurring funding for R&D |
| Upfront deal cash | About $125M | Non-dilutive balance-sheet support |
| Milestones and royalties | Up to $1.2B | Future cash without sales buildout |
What You See Is What You Get
Protagonist Therapeutics, Inc. Reference Sources
The Protagonist Therapeutics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content, no hidden changes—just the full, professionally formatted report ready to use. Download it instantly and use it for analysis, presentations, or strategic planning.
Dogs
No Approved Products
At the end of 2025, Protagonist Therapeutics had no approved or marketed product, so commercial sales were $0 and installed market share was nil. In BCG terms, that is the clearest "dog" profile: low share, low market maturity, and no cash flow from sales. The business was still a pure pipeline story, not a commercial one.
PN-943 Oral a4b7 Antagonist
PN-943 stayed a Dogs asset: Protagonist Therapeutics has not commercialized it, and ulcerative colitis market share is effectively 0. It is still far from adoption, so it has not started generating product revenue. In BCG terms, it keeps adding R&D spend without near-term cash inflow, which is a drag on capital efficiency.
Legacy Unpartnered Discovery Programs
Legacy unpartnered discovery programs at Protagonist Therapeutics, Inc. fit the Dog box because they are still earlier-stage peptide assets with no clear commercial traction yet. They keep consuming R&D cash, but their hit rate is still uncertain until human data proves a path forward. In BCG terms, they are low-share, high-risk programs that can stay value-dilutive until one shows strong clinical proof.
Non-Core Early Pipeline
Non-Core Early Pipeline assets at Protagonist Therapeutics, Inc. are classic Dogs: they sit outside rusfertide and the Janssen partnership, have limited visibility, and show no clear 2025 near-term sales path. With no established market share and no disclosed commercial traction, these programs look like low-return capital drains versus the lead assets.
- Low visibility
- No market position
- Weak near-term sales
- Capital better used elsewhere
Operating Losses Without Sales
Protagonist Therapeutics, Inc. stayed a Dogs case because it had no product sales to absorb operating losses, so cash burn still relied on external funding and partner economics. In FY2025, that made the portfolio structurally weak: collaboration receipts can help, but they do not replace recurring commercial cash flow. The result is a persistent drag on value until sales begin.
- No product sales
- Losses stay uncovered
- Funding dependence remains
- Partner income is not enough
Protagonist Remains Pre-Revenue, with No Approved Products or Sales
At the end of 2025, Protagonist Therapeutics, Inc. still fit the Dog box: no approved product, $0 product sales, and no market share. PN-943 and the early unpartnered pipeline remained low-share, pre-revenue assets that kept R&D cash flowing out without offsetting sales. Collaboration income helped, but it did not replace commercial cash flow.
| Metric | FY2025 |
|---|---|
| Product sales | $0 |
| Approved products | 0 |
| Market share | Nil |
| Commercial status | Pre-revenue |
Question Marks
Rusfertide in Hereditary Hemochromatosis
Rusfertide in hereditary hemochromatosis is a question mark: a follow-on use with real unmet need but no commercial base yet. Hereditary hemochromatosis affects about 1 in 200-300 people of Northern European ancestry, so the market is smaller than polycythemia vera, but positive data could open a new franchise. Protagonist needs funding to prove uptake, safety, and value.
Rusfertide in Other Iron-Overload Disorders
Rusfertide’s hepcidin-mimetic action could reach other iron-overload settings, not just polycythemia vera, giving Protagonist Therapeutics, Inc. some real option value. But as of 2025, it is still unapproved, so market share is 0 and commercial traction is unproven. That makes it a Question Mark in the BCG Matrix: high upside, but adoption, label breadth, and payer demand still need proof.
PN-943 Ulcerative Colitis Development
PN-943 is still a growth gamble, not a proven winner. Ulcerative colitis sits in a large market, with about 1 million U.S. patients and about 3 million people living with IBD, but Protagonist Therapeutics, Inc. has not built any competitive share yet. If PN-943 shows strong efficacy and safety, it can move toward a star; if not, it stays a question mark.
Icotrokinra Beyond Psoriasis
Icotrokinra’s move beyond psoriasis is a Question Mark: J&J is testing it in more immune-mediated diseases, but each new use still needs clear efficacy and uptake. The upside is real, since psoriasis already shows a large market path and J&J’s immunology base is strong, with Tremfya sales at $11.3 billion in 2025. Still, share is uncertain until later-stage data and payer buy-in land.
High growth, low share today
More indications expand upside
Clinical proof still the gate
New Peptide Discovery Pipeline
Protagonist Therapeutics’ new peptide discovery pipeline is a classic question mark: the engine can still generate the next wave of assets, but these programs are pre-revenue and have no market share yet. The upside is high if one or more candidates advance into clinical proof, but the cash need stays real because discovery-stage assets often take years to de-risk. In BCG terms, this is a clear "invest or wait" call.
- High upside, zero sales
- No market position yet
- Value depends on clinical success
Protagonist’s High-Upside Question Marks: Big Markets, Zero Share
Question marks in Protagonist Therapeutics, Inc. are still early, high-upside bets: rusfertide in hereditary hemochromatosis, PN-943 in ulcerative colitis, and the discovery pipeline. They sit at 0% share today, but each targets large unmet need; for example, ulcerative colitis affects about 1 million U.S. patients.
| Asset | Status | Signal |
|---|---|---|
| Rusfertide | Question mark | Unapproved, no sales |
| PN-943 | Question mark | Big market, no share |
| Pipeline | Question mark | Pre-revenue |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.